BR112015032379A2 - inibidores virais de replicação, seu processo de preparação e suas utilizações terapêuticas - Google Patents
inibidores virais de replicação, seu processo de preparação e suas utilizações terapêuticasInfo
- Publication number
- BR112015032379A2 BR112015032379A2 BR112015032379A BR112015032379A BR112015032379A2 BR 112015032379 A2 BR112015032379 A2 BR 112015032379A2 BR 112015032379 A BR112015032379 A BR 112015032379A BR 112015032379 A BR112015032379 A BR 112015032379A BR 112015032379 A2 BR112015032379 A2 BR 112015032379A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation process
- therapeutic uses
- viral replication
- replication inhibitors
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
- C07C59/13—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo inibidores virais de replicação, seu processo de preparação e suas utilizações terapêuticas a presente invenção se refere aos compostos, à sua utilização no tratamento ou prevenção de distúrbios virais, incluindo o hiv.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13305965.9A EP2821104A1 (en) | 2013-07-05 | 2013-07-05 | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
PCT/EP2014/064446 WO2015001125A1 (en) | 2013-07-05 | 2014-07-07 | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015032379A2 true BR112015032379A2 (pt) | 2017-07-25 |
Family
ID=48793140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015032379A BR112015032379A2 (pt) | 2013-07-05 | 2014-07-07 | inibidores virais de replicação, seu processo de preparação e suas utilizações terapêuticas |
Country Status (14)
Country | Link |
---|---|
US (1) | US9994509B2 (pt) |
EP (2) | EP2821104A1 (pt) |
JP (1) | JP6571645B2 (pt) |
KR (1) | KR20160030213A (pt) |
CN (1) | CN105492075B (pt) |
AU (1) | AU2014286074A1 (pt) |
BR (1) | BR112015032379A2 (pt) |
CA (1) | CA2916335A1 (pt) |
CL (1) | CL2015003752A1 (pt) |
ES (1) | ES2707675T3 (pt) |
HK (1) | HK1217457A1 (pt) |
MX (1) | MX364704B (pt) |
RU (1) | RU2678575C2 (pt) |
WO (1) | WO2015001125A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2772480B2 (en) † | 2011-10-25 | 2020-12-09 | Shionogi & Co., Ltd. | Hiv replication inhibitor |
EP2719685A1 (en) * | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
CN106496008A (zh) * | 2016-10-20 | 2017-03-15 | 上海毕得医药科技有限公司 | 一种合成4‑(4‑氯苯基)环己酮的方法 |
US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2842559A (en) | 1954-10-20 | 1958-07-08 | Wisconsin Alumni Res Found | Synthesis of estrone intermediates |
GB942663A (en) | 1960-04-06 | 1963-11-27 | Director | Phenyl cyclohexane and -cyclohexene derivatives, new intermediates for the synthesis of the female sex hormone estrone and other steroids |
IL59557A (en) | 1979-03-12 | 1983-10-31 | Lilly Co Eli | 1,1-biphenyl-2-yl propyl butyl and pentyl amines,their preparation and pharmaceutical compositions comprising them |
GB8330099D0 (en) | 1983-11-11 | 1983-12-21 | Ici Plc | Cycloalkane derivatives |
US4872918A (en) | 1986-05-12 | 1989-10-10 | Philip Morris Incorporated | Heterocyclic esters and smoking compositions containing a heterocyclic ester flavorant-release additive |
FR2772761B1 (fr) | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
AU742423B2 (en) | 1998-01-21 | 2002-01-03 | Msd K.K. | Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
JP4476232B2 (ja) | 2006-03-10 | 2010-06-09 | 三菱重工業株式会社 | 成膜装置のシーズニング方法 |
EP2001844A2 (en) | 2006-03-14 | 2008-12-17 | Amgen, Inc | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
WO2008128344A1 (en) | 2007-04-18 | 2008-10-30 | The University Of British Columbia | Small-molecule hepatitis c virus (hcv) ns3/4a serine protease inhibitors |
EP2574610A1 (en) | 2007-11-15 | 2013-04-03 | Gilead Sciences, Inc. | Inhibitors of human immonodeficiency virus replication |
US8377960B2 (en) | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
CN101918365B (zh) | 2007-11-16 | 2013-10-09 | 吉联亚科学股份有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
ES2463720T3 (es) | 2007-11-16 | 2014-05-29 | Gilead Sciences, Inc. | Inhibidores de la replicación del virus de inmunodeficiencia humana |
RU2379049C2 (ru) * | 2007-12-11 | 2010-01-20 | Олег Витальевич Калюжин | Средство для лечения вич-инфекции |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
KR20110086152A (ko) | 2008-11-14 | 2011-07-27 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이페닐아세트아미드 유도체 |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
EP2588455B1 (en) | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
ES2742261T3 (es) | 2011-04-15 | 2020-02-13 | Hivih | Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos |
UA111841C2 (uk) | 2011-04-21 | 2016-06-24 | Гіліад Сайєнсіз, Інк. | Сполуки бензотіазолу та їх фармацевтичне застосування |
EP2772480B2 (en) | 2011-10-25 | 2020-12-09 | Shionogi & Co., Ltd. | Hiv replication inhibitor |
EP2719685A1 (en) * | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
ES2731232T3 (es) * | 2013-03-15 | 2019-11-14 | Inst Nat Sante Rech Med | Método y composición farmacéutica para su uso en el tratamiento y la predicción del infarto de miocardio |
-
2013
- 2013-07-05 EP EP13305965.9A patent/EP2821104A1/en not_active Withdrawn
-
2014
- 2014-07-07 CA CA2916335A patent/CA2916335A1/en not_active Abandoned
- 2014-07-07 MX MX2016000037A patent/MX364704B/es active IP Right Grant
- 2014-07-07 CN CN201480043336.4A patent/CN105492075B/zh not_active Expired - Fee Related
- 2014-07-07 RU RU2015155438A patent/RU2678575C2/ru not_active IP Right Cessation
- 2014-07-07 ES ES14735599T patent/ES2707675T3/es active Active
- 2014-07-07 BR BR112015032379A patent/BR112015032379A2/pt not_active IP Right Cessation
- 2014-07-07 EP EP14735599.4A patent/EP3016714B1/en not_active Not-in-force
- 2014-07-07 US US14/902,955 patent/US9994509B2/en not_active Expired - Fee Related
- 2014-07-07 WO PCT/EP2014/064446 patent/WO2015001125A1/en active Application Filing
- 2014-07-07 AU AU2014286074A patent/AU2014286074A1/en not_active Abandoned
- 2014-07-07 JP JP2016522659A patent/JP6571645B2/ja not_active Expired - Fee Related
- 2014-07-07 KR KR1020167002741A patent/KR20160030213A/ko not_active Application Discontinuation
-
2015
- 2015-12-29 CL CL2015003752A patent/CL2015003752A1/es unknown
-
2016
- 2016-05-10 HK HK16105334.6A patent/HK1217457A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX2016000037A (es) | 2016-05-31 |
US20160152543A1 (en) | 2016-06-02 |
EP3016714B1 (en) | 2018-09-19 |
CL2015003752A1 (es) | 2016-08-05 |
JP2016527211A (ja) | 2016-09-08 |
US9994509B2 (en) | 2018-06-12 |
EP3016714A1 (en) | 2016-05-11 |
EP2821104A1 (en) | 2015-01-07 |
ES2707675T3 (es) | 2019-04-04 |
RU2015155438A3 (pt) | 2018-04-28 |
KR20160030213A (ko) | 2016-03-16 |
WO2015001125A1 (en) | 2015-01-08 |
RU2678575C2 (ru) | 2019-01-30 |
CN105492075A (zh) | 2016-04-13 |
JP6571645B2 (ja) | 2019-09-04 |
RU2015155438A (ru) | 2017-06-28 |
MX364704B (es) | 2019-05-06 |
HK1217457A1 (zh) | 2017-01-13 |
AU2014286074A1 (en) | 2016-01-21 |
CN105492075B (zh) | 2019-11-12 |
CA2916335A1 (en) | 2015-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013026427A2 (pt) | inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos | |
BR112015024414A2 (pt) | derivados de oxopiridina substituída e uso desses no tratamento de distúrbios cardiovasculares | |
CO2018000113A2 (es) | Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina | |
BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
BR112017013858A2 (pt) | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos | |
BR112014016971A8 (pt) | pirimidinas e triazinas fundidas substituídas e seus usos | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
IN2013MU01749A (pt) | ||
BR112013025769A2 (pt) | inibidores de replicação viral, seu processo de preparação e seus usos terapêuticos | |
UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
EA201590703A1 (ru) | Ингибиторы mek при лечении вирусных заболеваний | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
BR112018013833A2 (pt) | métodos de administração de hepcidina | |
BR112017003705A2 (pt) | compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea | |
BR112016023554A2 (pt) | novos compostos macrocíclicos | |
BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
BR112016006317A2 (pt) | Derivados de fenilalanina substituída | |
BR112015032379A2 (pt) | inibidores virais de replicação, seu processo de preparação e suas utilizações terapêuticas | |
BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
NI201900023A (es) | 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
BR112017016333A2 (pt) | compostos anticâncer | |
PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
BR112016024467A2 (pt) | compostos e métodos para a prevenção ou o tratamento da malária |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: HIVIH (FR) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2627 DE 11-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |